Drug . | KU812 . | K562 . | TCC-S . | TCC-Y . |
---|---|---|---|---|
ST1571 (nM) | 84 ± 9 | 247 ± 30 | 72 ± 6 | 510 ± 80 |
Recombinant IFN-α (IU/mL) | 4400 ± 500 | > 10 000 | 1500 ± 300‡ | 4500 ± 600 |
Natural IFN-α (IU/mL) | 2400 ± 400 | > 10 000 | 1100 ± 200‡ | 2800 ± 450 |
Hydroxyurea (mM) | 0.75 ± 0.04 | 1.1 ± 0.2 | 0.17 ± 0.02 | 0.52 ± 0.04 |
Cytarabine (nM) | 8.9 ± 1.1 | 92 ± 17 | 410 ± 56 | 5.1 ± 0.6 |
Homoharringtonine (nM) | 56 ± 3 | 92 ± 11 | 57 ± 6 | 80 ± 8 |
Doxorubicin (nM) | 27 ± 3 | 70 ± 6 | 39 ± 6 | 82 ± 11 |
Etoposide (μM) | 2.0 ± 0.2 | 4.2 ± 0.6 | 2.6 ± 0.4 | 2.1 ± 0.2 |
Hydroperoxy-cyclophosphamide (μM) | 4.8 ± 0.6 | 8.1 ± 0.6 | 5.3 ± 0.7 | 3 ± 0.5 |
Methotrexate (nM) | 14 ± 1 | 86 ± 7 | 52 ± 7 | 64 ± 9 |
Vincristine (nM) | 0.88 ± 0.03 | 7.1 ± 0.9 | 0.75 ± 0.03 | 0.66 ± 0.02 |
Drug . | KU812 . | K562 . | TCC-S . | TCC-Y . |
---|---|---|---|---|
ST1571 (nM) | 84 ± 9 | 247 ± 30 | 72 ± 6 | 510 ± 80 |
Recombinant IFN-α (IU/mL) | 4400 ± 500 | > 10 000 | 1500 ± 300‡ | 4500 ± 600 |
Natural IFN-α (IU/mL) | 2400 ± 400 | > 10 000 | 1100 ± 200‡ | 2800 ± 450 |
Hydroxyurea (mM) | 0.75 ± 0.04 | 1.1 ± 0.2 | 0.17 ± 0.02 | 0.52 ± 0.04 |
Cytarabine (nM) | 8.9 ± 1.1 | 92 ± 17 | 410 ± 56 | 5.1 ± 0.6 |
Homoharringtonine (nM) | 56 ± 3 | 92 ± 11 | 57 ± 6 | 80 ± 8 |
Doxorubicin (nM) | 27 ± 3 | 70 ± 6 | 39 ± 6 | 82 ± 11 |
Etoposide (μM) | 2.0 ± 0.2 | 4.2 ± 0.6 | 2.6 ± 0.4 | 2.1 ± 0.2 |
Hydroperoxy-cyclophosphamide (μM) | 4.8 ± 0.6 | 8.1 ± 0.6 | 5.3 ± 0.7 | 3 ± 0.5 |
Methotrexate (nM) | 14 ± 1 | 86 ± 7 | 52 ± 7 | 64 ± 9 |
Vincristine (nM) | 0.88 ± 0.03 | 7.1 ± 0.9 | 0.75 ± 0.03 | 0.66 ± 0.02 |